Novartis CDR (NOVN) 뉴스

Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockholders

DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today...

Current Report Filing (8-k)

false000146715400014671542023-05-312023-05-31UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 8-K   CURRENT...

Novan Focuses Strategic Direction and Announces Restructuring

– Company directing resources on the potential approval of berdazimer gel, 10.3% (SB206) for molluscum...

Quarterly Report (10-q)

false12/312023Q1000146715400014671542023-01-012023-03-3100014671542023-05-05xbrli:shares00014671542023-03-31iso4217:USD00014671542022-12-31iso4217:...

Current Report Filing (8-k)

false000146715400014671542023-05-152023-05-15UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 8-K   CURRENT...

Novan Reports First Quarter 2023 Financial Results and Provides Corporate Update

– Continued progress toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% (SB206) – – Strong...

Novan to Report First Quarter 2023 Financial Results on May 15, 2023

DURHAM, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today...

Novan Announces Publication of Psoriasis Patient Data Demonstrating Need for Rapid Symptom Improvement¹

Published results from a National Psoriasis Foundation-fielded survey included responses from more than 400...

Proxy Statement (definitive) (def 14a)

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549SCHEDULE 14A INFORMATIONProxy Statement Pursuant to Section 14(a) of the...

Novan to Host Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhD

DURHAM, N.C., April 20, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today...

Novan Reports Full Year 2022 Financial Results and Provides Corporate Update

– Berdazimer gel, 10.3% (SB206) assigned PDUFA goal date of January 5, 2024 – – Strong year-over-year...

Novan to Report Full Year 2022 Financial Results on March 30, 2023

DURHAM, N.C., March 23, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN...

Confidential Treatment Order (ct Order)

Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset

Children in LT-001 treated after SMA symptom onset maintained or achieved additional milestones up to 7.5 years...

Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer

New approval based on TADPOLE trial showing overall response rate (ORR) of 47% and median progression-free...